75 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Current Trends in Psychedelic Science: Integrating Modified Lysergic Acid Derivatives and Psilocybin in Modern Medicine.
Usona Institute
Advancements in Targeted Therapeutics: Integrating Metabolic Modulation, Immune Engineering, and Biologic Formulation Technologies.
Usona Institute
Treatment of Metabolic Disorders Using Novel DGAT2 Inhibitors: Pyrazolopyridine and Triazolopyridine Derivatives.
Usona Institute
Innovative Therapeutic Approaches Targeting K-Ras: Analysis of Macrocyclic Compounds, Peptidomimetics, and Pyridopyrimidine Inhibitors.
Usona Institute
Lysosomal Degradation of Extracellular Targets: Innovations and Implications.
Usona Institute
Development and Utilization of Novel Transglutaminase 2 Inhibitors for Potential Treatment of Autoimmune Disease and Gastrointestinal Disorder.
Usona Institute
Small-Molecule Heterocyclic Compounds: Gq-Biased Agonists for the 5-HT2A Receptor in Neuropsychiatric Treatment.
Usona Institute
PARP7 Inhibition: A Promising Pathway to Advancements in Cancer Therapy.
Usona Institute
New Horizons in Cancer Treatment: A Closer Look at Novel PI3Kα Inhibitors.
Usona Institute
Cyclin-Dependent Kinase Degradation via E3 Ligase Binding for Potential Disease Modulation in Cancer Treatment.
Usona Institute
Innovative Therapeutic Strategies in TYK2-Targeted Treatments: From Cancer to Autoimmune Disorders.
Usona Institute
Advancements in Predictive Medicine: NLRP3 Inflammasome Inhibitors and AI-Driven Predictive Health Analytics.
Usona Institute
PROTAC: Harnessing Targeted Chimeras for Selective BCL-2 Degradation in Cancer Treatment.
Usona Institute
Discovery of Selective Aldehyde Dehydrogenase Inhibitors for the Treatment of Cancer.
Usona Institute
Restoration of Motor Function Post-Neurological Injury Using Serotonergic Agonist.
Usona Institute
Ibogaine and Their Analogs as Therapeutics for Neurological and Psychiatric Disorders.
Usona Institute
Application of Rapidly Accelerating Fibrosarcoma Protein Degraders in Drug Discovery.
Usona Institute
KRAS Inhibitors and Target Engagement Technology: From Undruggable to Druggable Targets in Cancer Therapeutics.
Usona Institute
3-Pyrrolidine-indole Derivatives as 5-HT2-Selective Receptor Modulators for the Potential Treatment of Mental Disorders.
Usona Institute
Selective Cyclin-Dependent Kinase Inhibitors and Their Application in Cancer Therapy.
Usona Institute
Improved 5-HT2 Selective Receptor Modulators for the Treatment of Psychological Disorders.
Usona Institute
Improved Metabolically Stable 5-HT Receptor Modulators and the Development of New Antidepressants.
Usona Institute
Targeting KRAS G12D Mutant for the Potential Treatment of Pancreatic Cancer.
Usona Institute
Targeting KRAS Mutant Protein Inhibitor for Potential Treatment in Cancer.
Usona Institute
The Psychedelic Renaissance: Addressing Potential Adverse Effects in a Therapeutic Setting.
Usona Institute
Psilocin Derivatives as Serotonergic Psychedelic Agents for the Treatment of CNS Disorders.
Usona Institute
Modulation of KRAS Mutant by Inhibiting PLK1 Kinase in Cancer Therapeutics.
Usona Institute
Dual Inhibition of KRAS G12C and G12D Mutants as a Potential Treatment in Cancer Therapy.
Usona Institute
Small Molecule Inhibitors of KRAS Mutant as a Therapeutic Strategy for the Treatment of Cancer.
Usona Institute
Modulation of Androgen Receptor for Therapeutic Application in Cancer and Viral Infection.
Usona Institute
Selective DYRK1A Inhibitor for the Treatment of Neurodegenerative Diseases: Alzheimer, Parkinson, Huntington, and Down Syndrome.
Usona Institute
Targeting Stimulator of Interferon Genes (STING) for the Potential Treatment of Cancer and Infectious Diseases.
Usona Institute
Tumor-Targeted Bivalent Protein Degradation for Application in Cancer Therapy.
Usona Institute
Sigma-1 and Sigma-2 Receptor Modulators as Potential Therapeutics for Alzheimer's Disease.
Usona Institute
Synthesis and Biological Evaluation of Tryptamines Found in Hallucinogenic Mushrooms: Norbaeocystin, Baeocystin, Norpsilocin, and Aeruginascin.
Usona Institute
Selective Estrogen Receptor Degraders for the Potential Treatment of Cancer.
Usona Institute
Inhibition of ACSS2 for Treatment of Cancer and Neuropsychiatric Diseases.
Usona Institute
Modulation of Tropomyosin Receptor Kinase for the Treatment of Neurotrophin Diseases: Alzheimer's, Huntington's and Parkinson's.
Usona Institute
PROTAC-Mediated Degradation of Estrogen Receptor in the Treatment of Cancer.
Usona Institute
PROTAC Degradation of IRAK4 for the Treatment of Neurodegenerative and Cardiovascular Diseases.
Usona Institute
Treatment of Cancers by Inhibition of Isoprenylcysteine Carboxyl Methyltransferase.
Usona Institute
Toll-like Receptors for the Treatment of Autoimmune, Inflammation, and Infectious Diseases.
Usona Institute
Thiazole Derivatives as Inhibitors for the Treatment of Cancer Cells Resistant.
Usona Institute
Histone Deacetylase Inhibitors as Treatment for Targeting Multiple Components in Cancer Therapy.
Usona Institute
Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein.
Usona Institute
2,7-Diazaspiro[4,4]nonanes for the Treatment or Prevention of Cancers and Diabetes.
Usona Institute